Meta AnalysisID 6668
舒肝解郁胶囊治疗女性抑郁症的疗效与安全性：系统评价与Meta分析
CRD42021252366
The aim of the research of randomized controlled trials is to evaluate the efficacy and safety of the Shugan Jieyu capsule for depressive disorders in women.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6668
- Evidence Id
- 15226
- Core Evidence Id
- 15226
- Source Meta Analysis Id
- 6650
- Herb2 Meta Analysis Id
- HBMA006650
- Crd Id
- CRD42021252366
- Title
- Efficacy and safety of Shugan Jieyu capsule on treating female depression: a systematic review and meta-analysis
- Review Question
- The aim of the research of randomized controlled trials is to evaluate the efficacy and safety of the Shugan Jieyu capsule for depressive disorders in women.
- Study Type Included
- Only randomised controlled trials will be included.
- Condition Being Studied
- Depression. Depressive disorders in women.
- Participant
- Inclusion criteria: Women with a diagnosis of depressive disorders according to the criteria of the International Classification of Diseases 10 (ICD-10). Or Women with a diagnosis of depressive disorders according to the criteria of the Diagnostic and statistical manual of mental disorders(DSM-5). Exclusion criteria: - Participants with psychotic symptoms - Health comorbidities such as stroke, hypothyroidism, insomnia, heart failure, irritable bowel -Suicidal tendency, alcohol and drug dependence -research with obvious and uncorrectable errors or plagiarism.
- Animal
- Human Disease Modelled
- Intervention
- 1.Shugan Jieyu capsules alone 2.Shugan Jieyu capsules plus placebo or antidepressant monotherapy
- Comparator Control
- 1. Placebo or antidepressant 2. Antidepressant plus placebo or antidepressant monotherapy
- Main Outcome
- 1.HAMD: Change in depression score from baseline to the last available follow-up, measured using the Hamilton Depression Scale 2. MADRS: Change in depression score from baseline to the last available follow-up, measured using the Montgomery-Asberg Depression Rating Scale Measures of effect Before and after treatment, the period of treatment is evaluated.
- Outcome Measure
- Additional Outcome
- 1. HAMA: Change in anxiety score from baseline to the last available follow-up, measured using the Hamilton Anxiety Scale 2.SDS: Change in depression score from baseline to the last available follow-up, measured using the Self-rating depression scale 3. BDI: Change in depression score from baseline to the last available follow-up, measured using the Beck Depression Inventory 4.Adverse reaction rate. Measures of effect Standardized mean difference, Relative risks.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Depression; Drugs, Chinese Herbal; Female; Humans; Phytotherapy
- Contact
- Li Junnan [email protected]
- Organisational Affiliation
- Beijing University of Chinese Medicine http://english.bucm.edu.cn/
- Funding Source
- National Natural Science Foundation of China, number:81874422;81573843
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2021-06-12
- Registration Date
- 2021-07-13
- Anticipated Start Date
- 2021-03-28
- Anticipated Completion Date
- 2021-12-15
- Title Cn
- 舒肝解郁胶囊治疗女性抑郁症的疗效与安全性：系统评价与Meta分析
- Title En
- Efficacy and safety of Shugan Jieyu capsule on treating female depression: a systematic review and meta-analysis
- Bilingual Status
- complete